Pyrimidinylaminobenzamide derivatives and their use as inhibitors of tyrosine kinases
CA 2677313 C · Owner: Novartis Ag · Inventors: Breitenstein, Werner; Furet, Pascal; Manley, Paul William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to compounds of formula (I): (see formula I) wherein the substituents R1 R2 and R4 have the meaning as set forth and explained in the description of the invention to processes for the preparation of these compounds pharmaceutical compositions containing same the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity especially a neoplastic disease, in particular leukaemia and a method for the treatment of such disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 4, 2003 and granted January 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.